Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 3Turcot syndrome 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Locally Advanced Cervical Carcinoma 1Glioblastoma 1Gallbladder Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Oxaliplatin 21Capecitabine 17Fluorouracil 15Irinotecan 11Radiotherapy 10Leucovorin 8Cetuximab 6Bevacizumab 6Gemcitabine 5oblimersen 3fludarabine 3aldesleukin 3Nivolumab 3Erlotinib Hydrochloride 3Cyclophosphamide 3labetuzumab 2dehydroftorafur 2conatumumab 2Tomography, X-Ray Computed 2Receptor Protein-Tyrosine Kinases 2Radiation 2Panitumumab 2Neoadjuvant Therapy 2Magnetic Resonance Imaging 2Interleukin-2 2Gefitinib 2Electrocardiography 2Diphenhydramine 25,10-methylenetetrahydrofolic acid 2tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Rectal Neoplasms × Radiation Dose Hypofractionation × Clear all
NCT04636008 2024-08-06

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

West China Hospital

Phase 1/2 Recruiting
20 enrolled
Gastrointestinal

Turcot syndrome, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡